Big-name drugmakers play heart-drug roulette

Goodbye to Lipitor and Plavix; hello to new cardiovascular blockbusters? That's the gamble Big Pharma is taking, as drugmakers from Merck ($MRK) to Sanofi ($SNY) to GlaxoSmithKline ($GSK) sink beaucoups bucks into three types of potential heart treatments. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.